vs
Side-by-side financial comparison of BayCom Corp (BCML) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -416.2%, a 442.6% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-69.4M). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs -10.8%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
BCML vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $23.0M |
| Net Profit | $6.9M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | -428.9% |
| Net Margin | 26.5% | -416.2% |
| Revenue YoY | 9.4% | 78.8% |
| Net Profit YoY | 12.1% | 25.7% |
| EPS (diluted) | $0.63 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $23.0M | ||
| Q3 25 | $25.7M | $13.8M | ||
| Q2 25 | $24.7M | $14.2M | ||
| Q1 25 | $24.3M | $16.6M | ||
| Q4 24 | $23.7M | $12.9M | ||
| Q3 24 | $25.6M | $9.1M | ||
| Q2 24 | $23.8M | $7.0M | ||
| Q1 24 | $24.5M | $28.9M |
| Q4 25 | $6.9M | $-95.8M | ||
| Q3 25 | $5.0M | $-101.3M | ||
| Q2 25 | $6.4M | $-101.3M | ||
| Q1 25 | $5.7M | $-114.3M | ||
| Q4 24 | $6.1M | $-128.9M | ||
| Q3 24 | $6.0M | $-135.7M | ||
| Q2 24 | $5.6M | $-147.0M | ||
| Q1 24 | $5.9M | $-107.4M |
| Q4 25 | 36.6% | -428.9% | ||
| Q3 25 | 26.3% | -808.9% | ||
| Q2 25 | 35.3% | -772.2% | ||
| Q1 25 | 31.6% | -726.6% | ||
| Q4 24 | 34.2% | -1059.9% | ||
| Q3 24 | 32.4% | -1589.0% | ||
| Q2 24 | 31.9% | -1998.6% | ||
| Q1 24 | 33.3% | -394.0% |
| Q4 25 | 26.5% | -416.2% | ||
| Q3 25 | 19.5% | -735.2% | ||
| Q2 25 | 25.8% | -710.8% | ||
| Q1 25 | 23.4% | -687.6% | ||
| Q4 24 | 25.9% | -1001.2% | ||
| Q3 24 | 23.5% | -1489.5% | ||
| Q2 24 | 23.6% | -2112.6% | ||
| Q1 24 | 24.0% | -371.3% |
| Q4 25 | $0.63 | $-0.81 | ||
| Q3 25 | $0.46 | $-0.92 | ||
| Q2 25 | $0.58 | $-0.98 | ||
| Q1 25 | $0.51 | $-1.10 | ||
| Q4 24 | $0.55 | $-1.27 | ||
| Q3 24 | $0.54 | $-1.34 | ||
| Q2 24 | $0.50 | $-1.52 | ||
| Q1 24 | $0.51 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $671.4M |
| Total Assets | $2.6B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $338.6M | $671.4M | ||
| Q3 25 | $334.3M | $748.4M | ||
| Q2 25 | $330.6M | $715.3M | ||
| Q1 25 | $329.3M | $779.9M | ||
| Q4 24 | $324.4M | $872.0M | ||
| Q3 24 | $321.7M | $962.6M | ||
| Q2 24 | $315.3M | $971.1M | ||
| Q1 24 | $314.2M | $1.0B |
| Q4 25 | $2.6B | $842.1M | ||
| Q3 25 | $2.6B | $925.3M | ||
| Q2 25 | $2.6B | $898.9M | ||
| Q1 25 | $2.6B | $986.2M | ||
| Q4 24 | $2.7B | $1.2B | ||
| Q3 24 | $2.6B | $1.2B | ||
| Q2 24 | $2.6B | $1.2B | ||
| Q1 24 | $2.6B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-69.3M |
| Free Cash FlowOCF − Capex | $30.1M | $-69.4M |
| FCF MarginFCF / Revenue | 116.2% | -301.6% |
| Capex IntensityCapex / Revenue | 6.7% | 0.5% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-69.3M | ||
| Q3 25 | $7.3M | $-76.9M | ||
| Q2 25 | $6.4M | $-99.6M | ||
| Q1 25 | $9.3M | $-148.9M | ||
| Q4 24 | $30.4M | $-85.2M | ||
| Q3 24 | $9.6M | $-84.8M | ||
| Q2 24 | $7.7M | $-58.2M | ||
| Q1 24 | $5.1M | $-120.7M |
| Q4 25 | $30.1M | $-69.4M | ||
| Q3 25 | $6.2M | $-76.9M | ||
| Q2 25 | $5.6M | $-99.9M | ||
| Q1 25 | $9.1M | $-149.7M | ||
| Q4 24 | $28.7M | $-86.2M | ||
| Q3 24 | $9.4M | $-86.1M | ||
| Q2 24 | $7.4M | $-59.2M | ||
| Q1 24 | $3.9M | $-123.2M |
| Q4 25 | 116.2% | -301.6% | ||
| Q3 25 | 24.3% | -558.2% | ||
| Q2 25 | 22.8% | -701.0% | ||
| Q1 25 | 37.6% | -900.1% | ||
| Q4 24 | 121.1% | -669.4% | ||
| Q3 24 | 36.6% | -945.2% | ||
| Q2 24 | 31.2% | -850.9% | ||
| Q1 24 | 16.1% | -425.7% |
| Q4 25 | 6.7% | 0.5% | ||
| Q3 25 | 4.3% | 0.2% | ||
| Q2 25 | 3.0% | 1.7% | ||
| Q1 25 | 0.6% | 4.4% | ||
| Q4 24 | 7.2% | 7.6% | ||
| Q3 24 | 1.0% | 14.0% | ||
| Q2 24 | 1.0% | 14.5% | ||
| Q1 24 | 4.7% | 8.7% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
